Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00088751
Other study ID # 040247
Secondary ID 04-N-0247
Status Completed
Phase N/A
First received July 31, 2004
Last updated June 30, 2017
Start date July 23, 2004
Est. completion date June 1, 2009

Study information

Verified date June 1, 2009
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objectives. The proposed clinical study has two goals: First, to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD and second, to further characterize the biological markers, including genetic, imaging, and CSF proteins, of FTD in relation to our existing group of Alzheimer's patients.

Rationale. Frontotemporal dementia (FTD) is increasingly recognized as an important neuropsychiatric disorder. Symptoms of FTD include disinhibition, impulsivity, apathy, affective lability, and language dysfunction. The clinical syndrome is associated with frontal and/or anterior temporal atrophy on imaging and autopsy. Levels of the CSF proteins tau and (Beta)-amyloid 1-42, shown to have diagnostic utility in patients with Alzheimer's Disease (AD), have also been found to be abnormal in FTD. FTD is less associated with APOE genotype than AD, however some familial cases of FTD are associated with specific mutations in the gene encoding the tau protein. Currently, no treatments have been proven to be effective for altering the course or clinical symptoms of FTD.

Design. Study subjects will include 50 male and female patients with mild-moderate frontotemporal dementia recruited from participants in NINDS protocol 02-N-0001. In a double-blinded crossover 11-week study without a placebo control, patients will be treated with a stimulant (dextroamphetamine) and an atypical antipsychotic (quetiapine). The primary outcome measures will be the Neuropsychiatric Inventory and the Clinical Global Impression of Change. Cerebrospinal fluid, cognitive and genetic measures, brain MRIs, and side effects scales will also be collected.


Description:

Objectives. The goal of the proposed clinical study is to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD.

Rationale. Frontotemporal dementia (FTD) is increasingly recognized as an important neuropsychiatric disorder. Symptoms of FTD include disinhibition, impulsivity, apathy, affective lability, and language dysfunction. The clinical syndrome is associated with frontal and/or anterior temporal atrophy on imaging and autopsy. Currently, no treatments have been proven to be effective for altering the course or clinical symptoms of FTD.

Design. Study subjects will include 20 male and female patients with mild-moderate frontotemporal dementia recruited from participants in NINDS protocols 02-N-0001 and 81-N-0010. In a double-blinded crossover 11-week study without a placebo control, patients will be treated with a stimulant (dextroamphetamine) and an atypical antipsychotic (quetiapine). The primary outcome measures will be the Neuropsychiatric Inventory and the Clinical Global Impression of Change. Cognitive measures and side effects scales will also be collected.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 1, 2009
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 45 Years to 95 Years
Eligibility - INCLUSION CRITERIA:

1. FTD as diagnosed by the Lund-Manchester criteria including patients with diagnoses of Semantic Dementia or Primary Progressive Aphasia.

2. Ages 45 to 95 years old.

3. Mild-to-moderate (CDR 1 to 2) FTD with an assigned durable power of attorney.

EXCLUSION CRITERIA:

1. Diagnosis of any form of dementia besides FTD, including AD, Lewy body dementia, vascular dementia, dementia associated with Parkinson's disease, Corticobasal Degeneration and Progressive Supranuclear Palsy.

2. Severe dementia (CDR 3).

3. Known allergy or serious adverse reaction to quetiapine or dextroamphetamine.

4. Patient is already receiving a stimulant (methylphenidate, dextroamphetamine, pemoline, or modafinil), or an antipsychotic medication, typical or atypical, including prochlorperazine and metoclopromide.

5. Patients taking any of the following medications because of their potential interaction with dextroamphetamine: MAO use currently or within 14 days prior to start of study, Furazolidone, Guanethidine, norepinephrine, sibutramine, tricyclic antidepressants, carbonic anhydrase inhibitors.

6. Patients taking the following medications because of their potential interaction with quetiapine: Carbamazepine, clozapine, lithium, thioridazine.

7. History of CVA, or at significantly increased risk for CVA (e.g., atrial fibrillation, recent TIA etc.).

8. Symptomatic cardiovascular disease (i.e., angina, claudication, TIAs, syncope), uncontrolled hyper or hypotension, or a tic disorder.

9. Any medical contraindication to performing the procedures involved in the study including blood draws or lumbar puncture.

10. We will require a woman of child-bearing age to have a pregnancy test prior to starting the study medications and to use contraception during the course of the study.

11. Patients with a previous negative trial of a stimulant.

12. Patients with a history of severe psychosis.

13. Patients with a history of recent substance abuse.

14. Patients with QTc prolongation on a baseline EKG.

15. A score of 2 or less on the Communication Functional Ratings - Swallowing Domain.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997 Spring;9(2):231-9. Review. — View Citation

Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry. 1989 Jul;50(7):241-9. Review. — View Citation

Woods SW, Tesar GE, Murray GB, Cassem NH. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry. 1986 Jan;47(1):12-5. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Active, not recruiting NCT04516499 - Neurofilament Surveillance Project (NSP)
Recruiting NCT05456503 - PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620 Phase 3
Recruiting NCT03030586 - ADDIA Proof-of-Performance Clinical Study
Completed NCT02590276 - Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT00677885 - P-glycoprotein Function in Brain Diseases
Completed NCT02333942 - Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
Completed NCT00187525 - A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration Phase 4
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Completed NCT04287738 - Care Ecosystem: Navigating Patients and Families Through Stages of Care, Extension Trial N/A
Completed NCT02213458 - Care Ecosystem: Navigating Patients and Families Through Stages of Care N/A
Active, not recruiting NCT04937452 - Dopaminergic Therapy for Frontotemporal Dementia Patients Phase 2
Completed NCT03606798 - Multidisciplinary and Personalized Care of Behavioral Disorders in Frontotemporal Lobar Degeneration. N/A
Recruiting NCT01962064 - Social Cognition in Ageing and in Frontotemporal Lobar Degeneration N/A
Recruiting NCT05956834 - A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Enrolling by invitation NCT04635540 - Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease N/A
Completed NCT00604591 - Effects of Tolcapone on Frontotemporal Dementia Phase 2
Completed NCT03508024 - Patients With Alzheimer's Disease or Related Youth Disease
Completed NCT00613119 - PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
Recruiting NCT02964611 - Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration